Loading…
Loading…
Home › All recalls › Prescription medicine
Category
Prescription drugs recalled for contamination, potency or labelling.
Or try another category
1,993 recalls · newest first
CGMP Deviations: Presence of N-nitroso-duloxetine impurity above the recommended interim limit.
CGMP Deviations: presence of N-nitroso-duloxetine impurity above FDA recommended interim limit.
CGMP Deviations: Presence of Nitrosamine Drug Substance Related Impurity (NDSRI), N-Nitroso Nebivolol above acceptable intake (AI) limit.
Defective Container: Unable to get the solution out of the bottle as the spike of the cap was lodged in the nozzle of the product bottle.
Failed Dissolution Specifications
CGMP Deviations: the presence of a Nitrosamine Drug Substance Related Impurity (NDSRI), N-Nitroso-Duloxetine above the interim acceptable intake limit
CGMP Deviations; presence of N-nitroso-duloxetine impurity above recommended interim limit.
CGMP deviations: Presence of Nitrosamine Drug Substance Related Impurity (NDSRI), N-Nitroso-Cinacalcet above acceptable intake limit.
CGMP deviations: Presence of Nitrosamine Drug Substance Related Impurity (NDSRI), N-Nitroso-Cinacalcet above acceptable intake limit.
CGMP deviations: Presence of Nitrosamine Drug Substance Related Impurity (NDSRI), N-Nitroso-Cinacalcet above acceptable intake limit.
Lack of Assurance of Sterility; Improper crimps on vials impacting the integrity of the product
Failed Impurities/Degradation Specifications
Discoloration
Failed Stability Specifications
CGMP Deviations: Inconsistency in the water systems.
CGMP deviations: out of specifications for assay
Failed Impurities/Degradation Specifications
Subpotent and Superpotent Drug
Subpotent and Superpotent Drug
CGMP Deviations: Presence of N-nitroso-duloxetine impurity above recommended interim limit